Treatment with Tezepelumab Reduces Serum Interleukin (IL)-5 and IL-13 in Patients with Severe, Uncontrolled Asthma to Levels Approaching those Observed in Healthy Individuals - 01/02/21
Doi : 10.1016/j.jaci.2020.12.229
Tuyet-Hang Pham 1, Janet Griffiths, PhD 1, Gene Colice, MD 2, Jane Parnes, MD 3, Claudia Chen 4, Bill Cook 5
1 Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
2 Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
3 Amgen, Thousand Oaks, CA
4 Biometrics, Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
5 Respiratory & Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
175
Il testo completo di questo articolo è disponibile in PDF.Mappa
© 2020
Pubblicato da Elsevier Masson SAS.
Vol 147 - N° 2S
P. AB57 - Febbraio 2021 Ritorno al numero
Articolo precedente
- Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials
- Mark Liu, Camille Taillé, Jason Lee, Steven Smith, Steve Mallett, Neil Martin, Peter Howarth, Steven Yancey, Catherine Lemiere
- CAPTAIN: Effects of Body Mass Index (BMI) on Response to Triple Therapy in Patients With Inadequately Controlled Asthma on Inhaled Corticosteroids/Long-acting ?2-agonists (ICS/LABA)
- Diego Maselli, Sarah Chang, Andrew Fowler, Mark Liu, Michael Manning, David Mannino, Joseph Spahn, Agne Zarankaite, Edward Kerwin
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?